Flash FinanceUS
After hours S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Azora Therapeutics, Inc. (DE) (AZR)

Azora Therapeutics adds three directors, names Davidson board chair after four resignations

Neutral Impact 4 of 5 leadership

Azora Therapeutics appointed three new independent directors, Aida Habtezion, Paul Hastings and Thomas Soloway, effective November 3, 2026, and four directors resigned the same day, reducing the board to five members. Separately, 9,924,260 common shares were issued on conversion of Series A Preferred Stock, bringing common shares outstanding to 14,243,129 as of November 4, 2026.

Key points

  • Three directors appointed November 3, 2026: Aida Habtezion, M.D., Paul Hastings and Thomas Soloway; the board was reduced to five members
  • Four directors resigned effective November 3, 2026: J. Kermit Anderson, Cary J. Claiborne, Robertson H. Gilliland and Kevin Schuyler; Matthew Davidson was named board chair
  • 9,924,260 common shares issued on automatic conversion of 9,924.260 Series A Preferred shares effective November 2, 2026; 3,006.341 preferred shares remain outstanding
  • Company has not finalized non-employee director compensation; no equity awards granted to the new directors

The filing

CompanyAzora Therapeutics, Inc. (DE) (AZR)
Form8-K, current report
Filed with the SECNov 9, 2026, 7:30 AM ET
Accession number0001213900-26-117201

Items reported: 5.02 Director / Officer Change8.01 Other Events

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 7:35 AM ET, from this filing only.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.